понедельник, 26 сентября 2016 г.

Sanofi may win US approval of US$3 billion eczema drug by March

Sanofi may win US approval of US$3 billion eczema drug by March


French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential US$3 billion-a-year seller, by next March. French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016.



from Biotech News